Clinical Trials · NCT03879694
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Roswell Park Cancer Institute
- Enrollment
- 19
- Start date
- Jun 2019
- Locations
- 1 site, United States
- Primary endpoint
- Incidence of adverse events of SVN53-67/M57-KLH peptide vaccine in combination with octreotide acetate in patients with neuroendocrine tumors